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2Abstract25
26
Objectives:  The study evaluated the quality of compounded sachets and hard gelatine capsules and27
their feasibility in paediatric drug administration.28
Methods:  Commercial tablets were compounded to sachets and capsules in hospital environment,29
and the uniformity of content and simulated drug dose were determined.30
Key findings: Compounded formulations were successfully obtained for a range of drug substances;31
dipyridamole, spironolactone, warfarin and sotalol formulations were within acceptable limits for32
uniformity of content, in most cases. Though, some loss of drug was seen. The type and amount of33
excipients were found to affect uniformity of content; good conformity of capsules was obtained34
using lactose monohydrate as filler, whereas microcrystalline cellulose was a better choice in sachets.35
In capsules, content uniformity was obtained for a range of drug doses. If the drug is aimed to be36
administered through a nasogastric tube, solubility of the drug and excipients should be considered,37
as they were found to affect the simulated drug dose in administration.38
Conclusions:  Compounded sachets and capsules fulfilled the quality requirements in most cases. In39
compounding, the choice of excipients should be considered as they can affect conformity of the40
dosage form or its’ usability in practice. Quality assurance of compounded formulations should be41
taken into consideration in hospital pharmacies.42
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3Introduction47
The lack of age-appropriate formulations for paediatric medications is faced in everyday work48
in hospitals. Also, off-label use of medicines is common (1,2). In medication, extemporaneous49
preparations have to be used, although these have certain risks such as dosing inaccuracy or errors,50
excipient toxicity or modified bioavailability (3). Dosage forms and formulations are needed for51
paediatric use. In dosage forms, critical issues are dosing flexibility, accuracy and their practical52
handling. It has been evaluated that these issues concern even a quarter of existing dosage forms (3).53
Improvement needs concern even half of the marketed drug products when the ease of intake and54
palatability of the dosage form are taken into account. In improving the pharmaceutical quality of55
paediatric medicines the priority is on the youngest age groups, neonates and infants. Fortunately, an56
increased trend in the marketing authorisation procedures has been seen recently (4).57
Thus far, the need for compounding commercial products to paediatric dosage forms prevail58
in hospitals. The choice of dosage form type vary in different European countries (5). Liquid59
preparations are predominant in England and Sweden, capsules in France and powders in Finland.60
Also other manipulations, such as tablet splitting into segments or opening capsules are often61
necessary in paediatric medications (6), but risk for dose inaccuracy and chanced bioavailability is62
apparent in these manipulations (7,8,9). Facilities, time and expertise in hospital pharmacies limit the63
choice of what kind of compounded dosage forms are usually prepared (5). The practice in64
manufacture varies in the hospitals throughout Europe and there is little harmonisation of65
formulations. Many formulations are developed in-house, based on the literature available (if any).66
The quality of the formulations is usually evaluated indirectly, based on the batch records of67
procedures and ingredients. Often limited facilities are available for quality assurance, such as68
analytical equipment for evaluations of uniformity of content or stability of the drug.69
In Finland, compounding to solid dosage forms is common in hospital pharmacies; a70
commercial tablet is crushed and diluted with an appropriate filler and redistributed in smaller71
4strength sachets (powder paper) or capsules to obtain appropriately sized dosage units for paediatric72
medication (10). In practice, compounding to solid dosage forms has been considered feasible73
because solids are suitable for drug substances that are unstable in aqueous environment and thus74
cannot be compounded to suspensions or solutions (11). In general, solid dosage forms are expected75
to have better stability of the drug, although only few results of stability studies have been published76
for compounded capsules (12,13). Additionally, solid dosage forms may be preferable because less77
excipients are needed (14). This is important because many common excipients exhibit potential risk78
for toxicity in paediatric patients (15).79
However, little published information exists on compounded oral solid dosage forms, sachets80
and capsules. The information is in-house knowledge, and may be limited due to the lack of81
analytical facilities in hospital pharmacies. A Finnish research group has studied compounded sachets82
and hard gelatine capsules of one drug, nifedipine (10,16,17). They concluded that the optimum83
powder mass in sachets should be 300 mg or more, in smaller powders drug loss during manufacture84
increase the risk for non-conformity and low drug recovery. On the other hand, it was possible to85
prepare small capsules (size numbers 3 and 4), which complied the standards for uniformity of86
content. A French study evaluated the effect of the amount of the active ingredient on conformity of87
capsules, concluding that small amounts of drug increase the risk for non-conformity (18).88
Extemporaneous formulations that meet the quality standards could be compounded in these studies,89
but not all the formulations were such. It is evident that more information is needed, on more drug90
substances as well as on formulations containing different kinds of excipients. Although compounded91
formulations should be avoided, they still need to be used in hospitals. Thus, all the work towards92
compounded products which would be safe in use is extremely important.93
In the present study, the real life compounding of solid dosage forms in hospital pharmacy94
was mimicked, using the procedures and facilities available. The quality of sachets and hard gelatine95
capsules was evaluated, by determining their content uniformity as described in the European96
5Pharmacopoeia. Furthermore, the usability of the compounded solid dosage forms in paediatric drug97
administration was evaluated by mimicking the real administration procedure in hospitals (drug98
administration via nasogastric tube). In practice, the dosage form is opened before administration and99
the contents are administered with fluid or food (5). In the younger patients, the contents are100
suspended in water and administered through a nasogastric tube. Administration has been found101
challenging due to occasional blockage of the tube (19,20). The present study evaluated whether the102
formulation could explain difficulties in administration.103
Commercial tablets were compounded to sachets and capsules with different drugs and104
excipients in formulations. Drug substances were chosen based on their prevalence as commonly105
modified products in Finnish hospital pharmacies; dipyridamole, spironolactone, warfarin and106
sotalol. Additionally, warfarin and spironolactone were chosen based on their status as drugs107
included on the WHO Model List of Essential Medicines for Children (21). Although these drug108
substances are widely used in paediatric medication, no published information on the quality of109
compounded sachets or capsules is available. The risk for non-conformity was expected to be most110
evident with small-dose drugs (18). Thus, the effect of drug amount was studied with spironolactone111
and warfarin, which have the lowest therapeutic dose (of the four drugs). Sachets and capsules of112
different sizes were prepared, by varying the amount of filler in the formulation. Microcrystalline113
cellulose and lactose monohydrate were chosen because they are both widely used as excipients in114
paediatric medicines. Different grades of excipients were evaluated; microcrystalline cellulose,115
silicified microcrystalline cellulose and two grades of lactose monohydrate. These were chosen on116
the basis of their particle size and flow properties, which are expected to be important variables in117
preparation of the sachets and in the filling procedure of capsules which is standardized by volume118
(10). The effect of excipient grade was evaluated in more detail with sachets of the smallest weight.119
As the sachets are filled with weight, small weight sachets are expected to be most sensitive to dose120
non-conformity.121
6122
Materials and methods123
Materials in compounding124
Commercial tablets were compounded to sachets and hard gelatine capsules. Drug substances125
in these were dipyridamole (Dipyrin 75 mg, Ratiopharm; Merckle, Germany), spironolactone (Spirix126
25 mg, Takeda Pharma, Denmark), warfarin as a sodium salt (Marevan forte 5 mg, Orion Pharma,127
Finland) and sotalol as a hydrochloride salt (Sotalol Mylan 80 mg, Mylan; Gerard Laboratories,128
Ireland).129
Microcrystalline cellulose (MCC; Avicel PH-102, FMC Biopolymer, Ireland), silicified130
microcrystalline cellulose (SMCC; Prosolv 50, Penwest Pharmaceuticals Co, USA) and two grades131
of lactose monohydrate (Pharmatose, 200M and 80 M, DMV International, Netherlands) were used132
as fillers in formulations. Lactose monohydrate is freely but slowly soluble in water (1 in 5.24)133
whereas the celluloses are practically insoluble in water (22). In the MCC the average particle size134
was 100 µm and the values for bulk density and tapped density were 0.32 g/cm3 and 0.48 g/cm3,135
respectively. In the SMCC the corresponding values were 60 µm, 0.31 g/cm3 and 0.39 g/cm3. In136
Pharmatose 200 M the particle size was < 250 µm (fine particle fraction 60% < 45 µm) and values137
for bulk and tapped densities were 0.55 g/cm3 and 0.85 g/cm3, respectively. In Pharmatose 80 M the138
particle size was < 355 µm (fine particle fraction 10% < 100 µm), and the respective values for bulk139
and tapped densities were 0.76 g/cm3 and 0.91 g/cm3.140
141
Compounding to sachets and hard capsules142
Preparation of the sachets and hard capsules were done according to the standard protocol for143
extemporaneous compounding of dosage forms in hospital pharmacy, using the equipment and144
facilities available (Helsinki University Hospital, Finland, Päijät-Häme Central Hospital, Finland).145
Manufacturing procedures are the same in these units, but the choice of excipients in formulations146
7differ slightly (lactose is preferred in the first unit whereas MCC in the second).147
The commercial tablets were crushed manually and carefully ground into a fine powder, with148
a pestle in a non-porous mortar. The pestle was held firmly and downward pressure was exerted with149
it while the pestle was moved in concentric circles. Geometric amounts of filler were added to150
achieve a final drug concentration in formulation. Sachets were prepared to total weight of 200 mg151
(dipyridamole), 300 mg (sotalol) or 500 mg (spironolactone or warfarin). The theoretical amount of152
each drug was 5 mg (dipyridamole), 4 mg (sotalol), 0.5 mg (spironolactone) and 0.1 mg (warfarin).153
Each powder was weighed individually using an analytical balance (precision ± 0.05 mg) and154
transferred into waxed powder papers (Ulvila Paper Mill, Finland). One batch of each formulation155
was prepared for the production of 100 sachets.156
In preparation of the capsules, the amount of filler needed to fill the capsule was calculated157
and geometric amounts of filler were added to ground tablet mass to achieve the final volume of158
capsules. Hard gelatine capsules number 0 (volume 0.68 ml) were used for spironolactone and159
warfarin formulations, and capsules number 1 (volume 0.5 ml) were used for sotalol formulation. The160
theoretical amount of the drug in capsules was the same as in the sachets. Additionally, capsules161
containing higher amounts of drug were prepared for spironolactone and warfarin. Drug doses were 4162
mg for sotalol, 0.5 mg, 3 mg and 6 mg for spironolactone and 0.1 mg, 0.2 mg and 2 mg for warfarin.163
Capsules were filled with the Feton Fastlock capsule filling machine (Feton International, Belgium).164
Parallel batches were prepared for the production of 100 hard capsules. Because the capsules are165
filled with volume, variation in the powder mass and thus variation in the filling procedure may result166
in batch to batch variability.167
As a comparison to the semi-automated procedure (Feton) which is commonly used in168
Finnish hospitals, capsules were prepared with an automated procedure. These capsules were169
manufactured by Mettler Toledo Gmbh (Switzerland), using an automated Quantos capsule filling170
device (QH012-LNM, Mettler Toledo AG, Switzerland). The powder mass was prepared in hospital171
8pharmacy, as described previously, and the obtained drug powder was sent to Mettler Toledo for172
capsulation. The reference capsules contained the lowest amount of drug; spironolactone (0.5 mg) or173
warfarin (0.1 mg).174
175
Drug analysis by HPLC176
Drug concentrations were determined by means of high performance liquid chromatography177
(HPLC). Previously described methods with slight modifications were used in analysis (dipyridamole178
(23), spironolactone (24); warfarin sodium (25); sotalol hydrochloride (26)).  Samples containing179
sotalol hydrochloride were analysed in the Department of Environmental Sciences, all the other drugs180
were analysed in the Division of Pharmaceutical Chemistry and Technology.181
The HPLC system (Shimadzu Corporation, Japan, for sotalol hydrochloride; Thermo182
Separation Products TSP, USA, for the other drugs) consisted of degasser (Shimadzu DGU-20 A5;183
TSP Spectra System SCM 1000 vacuum membrane degasser), a pump (Shimadzu LC-20AT; TSP184
Spectra System P4000), autosampler (Shimadzu SIL-20-A; TSP Spectra System SA 3000), a UV-185
VIS detector (Shimadzu SPD-20A; TSP Spectra System UV 6000 LP) and a computerized data186
analysis system (Shimadzu Corporation LabSolutions 5.57 SP1, Japan; CromQuest 4.2.32, Thermo187
Scientific, USA).188
Sample separation was carried out in a reverse phase C-18 column (Synergi Hydro-RP 4.6189
mm x 25 cm; 4µm, USA for sotalol hydrochloride; Supelco Discovery 4.66 mm x 15 cm; 5 µm, USA190
for the other drugs). Retention times varied from 4.3 to 4.7 minutes for the analytes.191
The mobile phase consisted of methanol and phosphate buffer pH 4.6 (in a ratio of 75:25) for192
dipyridamole. For spironolactone, the mobile phase was methanol and HPLC grade water (65:35).193
For warfarin sodium, the mobile phase consisted of acetonitrile and HPLC grade water with 0.05% of194
trifluoroacetic acid (55:45). For sotalol hydrochloride, the mobile phase was acetonitrile and195
phosphate buffer pH 4.6 (75:25). The flow rate of the mobile phase was 1.0 ml/min.196
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Uniformity of content198
Content uniformities of dosage units (commercial tablets and compounded solid formulations199
thereof) were determined by method established in the European Pharmacopoeia. The dosage unit200
complied the test if not more than one of 10 individual contents was beyond ±15% of the average201
content and if none were beyond ±25% of the average content. If two or three individual contents202
deviated more than ±15% (but less than ±25%), the individual contents of another 20 dosage units203
were determined. The drug concentrations were analysed in triplicate by HPLC.204
205
Statistical analysis206
Statistical analysis were carried out in SPSS (IBM SPSS Statistics, Ver. 23, United States)207
using non-parametric Kruskal-Wallis analysis of variance. Individual differences were identified208
using Dunnet’s two-tailed t-test as a post hoc test. The value P<0.05 was considered as statistically209
significant.210
211
Simulation of drug administration212
Dosage form administration to paediatric patients in hospitals was simulated mimicking the213
administration procedure through a nasogastric tube (Helsinki University Hospital, Finland, Päijät-214
Häme Central Hospital, Finland). Individual contents of the dosage forms were emptied to a215
medicine cup and suspended to HPLC grade water. The volume of water varied depending on the216
procedure that they use in the hospital; 1.5 millilitres of water was used for suspending the contents217
of size 1 hard gelatine capsules, and for suspending the contents of size 0 hard gelatine capsules or218
sachets the volume was 3 millilitres. The suspension was thoroughly stirred with the tip of an oral219
syringe (volume 5 ml) after which the formed suspension was withdrawn into the syringe for drug220
administration. Nasogastric tube (Nutrisafe 2, size 06 French/50 cm, internal diameter 1.2 mm,221
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external diameter 2 mm, VYGON, France) was first rinsed with 2 millilitres of water, after which the222
drug suspension was administered through the tube. Finally, the tube was rinsed with 2 millilitres of223
water. All contents were led to a volumetric flask and after diluting the sample to a known volume,224
the amount of drug was analysed by HPLC. The simulated drug dose passed through the nasogastric225
tube was expressed as percentage of the average amount of the drug in formulation. The procedure226
was repeated in triplicate for each formulation.227
228
Results229
230
Content uniformity of commercial tablets231
All commercial tablets complied the test for uniformity of content, as expected. The average232
contents of drug in tablets were 77.6 mg ± 3.5 mg (SD) for dipyridamole (103.5% of the theoretical233
drug amount, which was labelled to be 75 mg), 24.2 mg ± 0.3 mg for spironolactone (98% of the234
labelled amount 25 mg), 4.96 mg ± 0.08 mg for warfarin (99.2% of the labelled amount 5 mg) and235
72.1 mg ± 1.4 mg for sotalol (90.1% of the labelled amount 80 mg).236
237
Content uniformity of compounded sachets238
The content uniformity of sachets, compounded with different fillers as excipients, complied239
the test for uniformity of content for most formulations (Table 1). However, if lactose of smaller240
particle size (< 250 µm) or microcrystalline cellulose were used as fillers, the formulation failed to241
comply with the test. In case of MCC formulations, two individual contents were outside the limits242
85 per cent to 115 per cent of the average content, and one was outside the limit of 75 per cent to 125243
per cent, in which case the deviation was 26.3% of the average content. For lactose formulation244
(particle-size grade < 250 µm), one content was outside the limit of 75 per cent to 125 per cent245
(measured value –30.7%).  The average drug content in formulations containing the different246
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excipients (MCC, SMCC or lactose, two grades) was found statistically significantly different247
(P<0.05) (Table 1).248
Although most of the formulations complied the test for uniformity of content, the mean drug249
content in compounded sachets was in most cases less than the theoretical drug content (Table 1).250
The difference was statistically significant (P<0.05) for most of the formulations (5/7). The251
adsorption of the drug in powder paper seemed one possible explanation for the loss of active252
ingredient, as visualised in Figure 1 for the yellowish drug dipyridamole. At highest, 16% (0.8 mg;253
SD ± 0.13 mg; n=5) of the labelled dose of dipyridamole was recovered from the sachet paper254
(formulation containing lactose particle-size grade < 355 µm). In analysis, the paper was rinsed with255
water and the drug analysed by HPLC. The drug loss was smallest when SMCC was used as filler in256
sachets, 3.8% (0.2 mg; SD ± 0.02 mg; n=5) of the labelled dose of dipyridamole was recovered from257
the sachet paper. The rest of the missing dose was assumed to be on the manufacturing tools.258
259
Content uniformity of compounded capsules260
The content uniformity of hard capsules compounded using lactose as filler complied the test261
for uniformity of content (Table 2). Content uniformity of hard capsules of spironolactone and262
warfarin were studied at three different dose levels. The largest single-capsule deviation from the263
mean content was 21% for capsules that contained the lowest amount of spironolactone (0.5 mg). The264
measured mean drug content in the batch was 0.42 mg which was lower (P<0.05) than the theoretical265
amount of drug (84.4% of the labelled dose). Also for warfarin, the highest single-capsule deviation266
(–8.2%) was observed with a batch of capsules which contained the lowest amount of drug (0.1 mg).267
In the batch, the measured mean drug content was 90% of the theoretical amount of drug, although268
the effect was not statistically significant in this batch.269
270
If microcrystalline cellulose was used as a filler in hard capsules (drug sotalol), one batch out271
12
of three did not comply the test for uniformity of content (Table 2). The highest single-capsule272
deviation was 25.2% which was slightly above the upper acceptation limit. In all batches the273
measured mean drug content was lower compared to the theoretical amount of the drug (4 mg). The274
average amount of drug varied from 3.7 mg (SD ± 0.09 mg, P<0.05) to 3.72 mg (SD ± 0.39 mg,275
P<0.05), which corresponded 92.5% to 93.0% of the theoretical amount of the drug.276
In most cases, no statistically significant effects were found in relation to batch to batch277
variation. Only two batches out of 15 parallel batches differed significantly (P<0.05) in the average278
drug content (Table 2).279
Capsules were also prepared with an automated Quantos capsule filling device, as a280
comparison to the conventional method (Feton). The batches prepared using Quantos complied with281
the content uniformity test specified in the European pharmacopoeia, as expected. Segregation of282
powder components during the filling process was not observed (Figure 2). The filling method had283
no effect on the quality of the capsules, and no statistically significant differences were found in the284
average drug content if capsules filled with Quantos were compared to capsules filled with the285
conventional method.  The largest single-capsule deviation from the mean content was 10%286
(spironolactone 10.24%; warfarin 10.20%; filler lactose). The average amount of drug in capsules287
was 0.41 mg (SD ± 0.017 mg) for spironolactone and 0.093 mg (SD ± 0.0038 mg) for warfarin,288
which corresponded 82.0% and 93.0% of the theoretical amount of the drug (0.5 mg and 0.1 mg for289
spironolactone and warfarin, respectively). The difference in drug amount was statistically significant290
(P<0.05) for spironolactone (no statistical effects were found for warfarin).291
292
Simulation of drug administration through a nasogastric tube293
The loss of drug was evident when suspended formulations were lead through a nasogastric294
tube, mimicking the procedure used in hospitals in administering the drug to the paediatric patient.295
The lowest simulated drug doses were obtained with sachets that contained celluloses (MCC or296
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SMCC) as fillers, compared to formulations that contained lactose. In these, the amount of297
dipyridamole passed through the nasogastric tube (n=3) varied from 46.5% (SMCC) and 62.0%298
(MCC) to 77.5% (lactose < 355 µm) and 86.1% (lactose < 250 µm) of the average drug content.299
In compounded hard gelatine capsules the drug loss was smaller than 12% of the average drug300
content in all cases. For size 0 hard gelatine capsules, the drug dose passed through the nasogastric301
tube (n=3) was 88.1% for spironolactone and 96.4% for warfarin (as sodium salt), calculated of the302
average drug content in the capsules. The filler in these capsules was lactose (particle-size grade <303
355 µm).  For size 1 hard gelatine capsules, 90.3% (n=10, P<0.05) of the drug dose passed through304
the tube (drug sotalol hydrochloride, filler MCC).305
Blockage of the nasogastric tube during drug administration was occasional, in most cases306
with no clear correlation to the type of the formulation. However, some tendency towards more307
frequent blockage was observed with formulation in which there was a combination of the slightly308
soluble drug dipyridamole and the practically insoluble, but swellable excipients MCC or SMCC.309
310
Discussion311
Finnish studies have presented extemporaneously compounded oral powders and capsules as a312
feasible choice for delivering paediatric medications (nifedipine) in hospital environment (10,16,17).313
The results of the present study demonstrate that, when needed, compounded solid dosage forms can314
successfully be obtained also for a range of other drug substances which are commonly used in315
paediatric medication in Finnish hospitals; in most cases, formulations of dipyridamole,316
spironolactone, warfarin and sotalol were found to be within acceptable limits for content uniformity,317
as described in the European Pharmacopoeia. In statistical analysis, no significant differences existed318
in average drug content when sachets were compared to capsules, indicating that both dosage forms319
are as good as a choice. However, the actual drug content in both dosage form types, sachets and hard320
gelatine capsules, was generally smaller than the theoretical amount of the drug. In 19 batches out of321
14
24 the difference was statistically significant (P<0.05).322
The findings on lower drug contents compared to the theoretical drug amount could partly be323
explained by the fact that the commercial tablets, which were used as a source of the active drug324
substance, may have contained less drug than labelled. Although the amount of drug was on an325
acceptable level in all products, the commercial tablets are allowed to have this kind of specific326
variation in drug content. Additionally, the drug adsorption on the surface of the dispenser or the loss327
of drug during the preparation process are possible explanations for low drug recovery (10,16). The328
drug loss has been found to be more marked with small size oral powders (mass 50 mg or 100 mg)329
dispensed in sachets, in which the drug recovery was only 62-77% of the theoretical value. A total of330
75% of the missing drug dose was found on the sachet paper (16). In compounded capsules (capsule331
shells size 1, 3 or 4) the drug recovery was satisfactory, which apparently related to the smaller332
surface area of the dispenser; capsule shell compared to sachet paper (10). In our study, the dosage333
units were in general larger (mass in the sachets varied from 200 mg to 500 mg, and the capsule shell334
size from 1 to 0) than in the previous study and thus, not so marked drug loss was expected.335
However, the phenomenon of drug adsorption on the surface of the sachet paper was easily visualised336
with the yellowish drug dipyridamole. In analysis, at highest 16% of the theoretical dose was found337
on the sachet paper (formulation containing lactose as filler). The risk of drug loss should be kept in338
mind in sachet formulations, especially if small sachets are prepared. Also, further studies would be339
beneficial in evaluations on whether other sachet materials than waxed powder paper could result in340
smaller drug loss, such as plastic laminates or foil.341
Although sachets and hard gelatine capsules were successfully compounded from commercial342
tablets in most cases, our results emphasize that the type and amount of excipients in the formulation343
should be considered as they can affect conformity of the dosage form. In statistical analysis, the344
effect of excipient was found significant in all cases, and formulations which contained the different345
excipients (MCC, SMCC and lactose, two grades) differed in average drug content. If the quality of346
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the formulations was evaluated as described in the European Pharmacopoeia, in total of three batches347
(out of 24 batches) failed to pass the test for content of uniformity; two of these were compounded as348
sachets (weight 200 mg) and one was a batch of hard gelatine capsules (capsule size 1). The sachets349
are filled by weight, and therefore inaccuracy of weighing procedures of the small amounts may be a350
challenge (10). Consistently in our study, the non-conformity in sachets was observed in the smallest351
sachet mass. Drug adsorption on the surface of the sachet paper or the equipment during preparation352
seemed possible explanations for non-conformity, as discussed earlier for sachets containing lactose353
(drug dipyridamole). It has been proposed that use of microcrystalline cellulose as filler could yield354
in better conformity in sachets (10). The smaller density of MCC results in larger volume of powder,355
which may protect against the drug adsorption to the sachet paper. Our results emphasise that in356
addition to density, also other powder characteristics may be important. The best drug recovery and357
less variation in uniformity of content of dipyridamole was obtained with silicified MCC, in which358
case not only the small density of the filler but also the surface properties of the excipient, such as359
hydrophobicity, may explain the results.360
Whereas the sachets are filled by weight, capsules are filled with volume. Thus, in preparation361
of capsules good flow properties of the filler are expected to result in better conformity (10). In362
general, higher density grades of fillers have improved flow properties (27). In addition, the amount363
of drug is known as a critical variable in compounded capsule formulations, and small amounts of364
drug increase the risk for non-conformity (18). In the present study, all 14 batches of capsules which365
contained lactose as filler complied the test for uniformity of content. On the other hand, in MCC366
capsules one batch of capsules out of three failed the test. The good conformity of lactose capsules367
may be explained by the high bulk and tapped densities of lactose, which could result in uniform368
filling of capsule shells during the manufacturing process. It was noteworthy, that content uniformity369
(as described in the European Pharmacopoeia) was obtained for a range of drug doses (from 0.1 mg370
to 2 mg for warfarin and from 0.5 mg to 6 mg for spironolactone), including the small doses of the371
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drug. In most cases, no statistically significant effects were found in relation to batch to batch372
variation. This indicates that compounding of such formulations is rather reproducible.  However, it373
should be noted that the measured drug content in the batches was predominantly significantly lower374
than the theoretical amount of the drug, although the batches met the pharmacopeial requirements.375
Discrepancy between the results could be explained by the fact that the limits of acceptance are376
calculated of the average drug content of the batch (instead of labelled drug amount).377
The last part of the study evaluated the practical usability of compounded sachets and378
capsules. Both sachets and capsules, whose contents are emptied for use, seem feasible choice from379
quality perspective (uniformity of content), and are a practical choice for manufacture in hospital380
pharmacies. In comparison to sachets, manufacture of capsules is faster as serial production can be381
utilised. This increases the usability of compounded capsules even further. Capsules filled with the382
Feton Fastlock filling machine were as good in quality as the reference capsules which had been383
filled using the automated Quantos capsule filling device. Despite of these favourable properties,384
there might be some concerns in practical use of compounded sachets and capsules. Including the385
capsules prepared with the Quantos capsule filling device, the risk of drug loss in manufacture and386
consequent possibility to under dosing should be considered. In addition, administration of these387
kinds of solid dosage forms (suspended in fluid) through the nasogastric tube has been found388
challenging (19,20).  The volume of water (or other fluid such as milk) in which the solid powder is389
suspended, should be rather small as the daily intake of fluids in the neonates is limited.  The small390
volume of fluid increases, however, the risk of blockage of the nasogastric tube. In our study, the391
administration through a nasogastric tube resulted in loss of drug. The lowest simulated drug doses392
were obtained with sachets which contained the slightly soluble (but swellable) excipient,393
microcrystalline cellulose, compared to formulations which contained the more readily soluble394
lactose. Similarly, the amount passed through the tube was slightly less for the insoluble drug395
spironolactone than for the readily soluble warfarin sodium. Such drug loss in administration,396
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together with the fact that the actual dose of drug was in most formulations less than the theoretical397
dose, increases the risk for under dosing in practice, especially for the drugs of narrow therapeutic398
index (such as warfarin in the present study).399
The results emphasize that in compounded sachets and capsules (if the dose is aimed to be400
administered through a nasogastric tube) solubility of the drug and excipients should be considered.401
The amount of solid contents should also be as small as possible as the amount of liquid used for402
suspending cannot be increased due to physiological reasons. This is supported by findings for size 1403
capsules, in which the drug administration through nasogastric tube resulted in high simulated drug404
dose, even though the formulation contained the slightly soluble excipient MCC. Also from the405
therapeutic point of view, smaller amount of excipients would be preferable as the safety of many406
excipients in the very young patients is not known (15). In practice, this means preference for407
compounding sachets of small weight and capsules of small size. The risk of drug loss should,408
however, be kept in mind.409
It is evident that more studies are needed in evaluations on how the formulation and410
excipients, or their administration procedure to the patient affect bioavailability of extemporaneous411
formulations. Also, in vitro studies predicting biological properties of the developed formulations are412
needed, such as dissolution studies. Unfortunately, the lack of facilities (analytical facilities,413
dissolution apparatus etc.) in hospital pharmacies has limited conductance of these studies.414
415
Conclusions416
Our results indicate that compounded formulations, which meet the quality requirements for417
uniformity of content as described in the European Pharmacopoeia, can successfully be obtained for a418
range of drug substances. The results emphasize, however, that the type and amount of excipients in419
the formulation should be considered.  Good conformity of capsules was obtained using lactose420
monohydrate as filler, whereas microcrystalline cellulose seemed a better choice in sachets. In lactose421
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capsules content uniformity could be obtained for a range of drug doses, including the very small422
doses. If the drug is aimed to be administered through a nasogastric tube, solubility of the drug and423
excipients should be considered, as they were found to affect the simulated drug dose in424
administration. The risk of drug loss should be considered in manufacture and administration. It is425
noteworthy that even though the formulations met quality requirements for uniformity of content, in426
most cases the measured drug content was statistically significantly lower than the theoretical amount427
of the drug.428
Both sachets and capsules could be a practical choice as solid dosage forms to be prepared in429
hospital pharmacies. Capsules are faster to manufacture, which increases their value even more430
compared to sachets. It is obvious, however, that validation of manufacturing procedures and quality431
assurance systems are important in hospital pharmacies, as the conformity is affected by the432
formulation. In compounding, the risk of drug loss should be kept in mind and analytical methods433
would be needed to determine the drug amount in quality analysis, or the influence of procedures434
(crushing the tables) on drug. Additionally, compatibility and stability studies are needed if435
compounded formulations are manufactured for storage, in addition to extemporaneous preparation.436
Dissolution studies would be needed to predict the biological properties of the developed437
formulations.438
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TABLES
Table 1.  Uniformity of content in compounded sachets. Individual contents of at least 10 units were
determined, as described in the method by European Pharmacopoeia.
Drug;
Excipient
Average
drug
content
(mg)
Acceptable
± 15% limits
(mg)
Largest
individual
deviation
(mg)
Maximum
deviation
 (%)
Amount of
drug  (% of
theoretical)
Dipyridamolea
MCC 4.52f,g 3.84 – 5.20 1.18 +26.3 90.4
SMCC 5.33f,g   4.54 – 6.13 0.69 –12.9e 106.6
Lactose (< 355 µm) 4.04f,g  3.43 – 4.65 0.52 +12.9e 80.8
Lactose (< 250 µm) 4.46f,g 3.79 – 5.13 1.37 –30.7 89.2
Spironolactoneb
Lactose (< 355 µm) 0.44f 0.37 – 0.51 0.04 +9.0e 88.0
Warfarin (as sodium
salt)c
Lactose (< 355 µm)
Sotalol (as
hydrochloride salt)d
MCC
0.092
3.69
0.078 – 0.106
3.14 – 4.23
0.009
0.17
+10.2e
–4.6e
92.0
92.2
Theoretical drug content (powder mass)  a 5 mg (200 mg); b 0.5 mg (500 mg); c 0.1 mg (500 mg); d4 mg
(300 mg); eComplies with the test for Uniformity of Content (European Pharmacopoeia);
fStatistically significantly different (P<0.05) from the labelled amount of drug; gStatistically significantly
different (P<0.05) when one excipient (MCC, SMCC or lactose) is compared to the other excipient.
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Table 2.  Uniformity of content in compounded hard gelatin capsules. Individual contents of at least
10 units were determined, as described in the method by European Pharmacopoeia.
Drug;
Theoretical
drug content
Average
drug
content
(mg)
Acceptable
± 15% limits
 (mg)
Largest
individual
deviation
(mg)
Maximum
deviation
(%)
Amount of
drug  (% of
theoretical)
Average
capsule
content
(mg)
Spironolactonea
0.5 mg 0.424d 0.360 – 0.487 0.089 +21.0c 84.4 552.4
0.5 mg 0.402d 0.342 – 0.462 0.006 –1.7c 80.4 556.3
0.5 mg 0.426d 0.362 – 0.489 0.017 –4.0c 85.2 553.3
3 mg 2.58d 2.19 – 2.97 0.24 –9.4c 86.0 545.6
6 mg 5.25d,e 4.47 – 6.04 0.43 +8.1c 87.5 536.1
6 mg 4.88d 4.15 – 5.61 0.25 –5.2c 81.3 545.8
6 mg
Warfarin
(as sodium salt)a
5.02d 4.27 – 5.77 0.18 –3.5c 83.7 544.4
0.1 mg 0.082d,e 0.070 – 0.095 0.006 –7.0c 82.0 530.1
0.1 mg 0.094 0.080 – 0.108 0.001 –1.2c 94.0 522.1
0.1 mg 0.090 0.076 – 0.103 0.007 –8.2c 90.0 486.5
0.2 mg 0.187d 0.160 – 0.216 0.010 –5.5c 93.5 512.1
2 mg 1.89d 1.60 – 2.17 0.07 +3.5c 94.5 509.2
2 mg 1.84d 1.56 – 2.11 0.12 –6.5c 92.0 521.0
2 mg
Sotalol (as
hydrochloride
salt)b
1.86d 1.58 – 2.14 0.07 +3.7c 93.0 521.7
4 mg 3.72d 3.16 – 4.28 0.13 –3.5c 93.0 186.8
4 mg 3.70 3.14 – 4.25 0.93 –25.2 92.5 180.6
4 mg 3.70d 3.15 – 4.26 0.38 –10.4c 92.5 173.0
a Capsule size 0, filler lactose monohydrate, particle-size < 355µm; b Capsule size 1, filler MCC, particle size <
100µm, cComplies with the test for Uniformity of Content (European Pharmacopoeia)
dStatistically significantly different (P<0.05) from the labelled amount of drug; eStatistically significantly
different (P<0.05) when the batch is compared to parallel batches. When capsules were compared to sachets
containing the same drug substance, at the same dose (Table 1.), no statistically significant effects were
detected (N.S.).
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Figure legends515
516
Figure 1. Visualisation of the adsorption of the yellowish drug dipyridamole on the sachet paper.517
Formulations (powder mass 200 mg) were dispensed in sachets, similarly as in preparation of the518
compounded solid dosage forms, and emptied for analysis. Formulations contained the different519
excipients (order of emptied sachet papers from front to back); SMCC, lactose monohydrate (particle520
size < 250 µm), MCC and lactose monohydrate (particle size < 355 µm).521
522
Figure 2. Drug content of capsules prepared using the automated Quantos (Mettler Toledo) capsule523
filling device; upper panel spironolactone (theoretical drug amount 0.5 mg, n = 30), lower panel524
warfarin (theoretical drug amount 0.1 mg, n = 20). The batches complied with the content uniformity525
test, as specified in the European pharmacopoeia. The acceptance ± 15% limits were 0.340 mg –526
0.472 mg and 0.079 mg – 0.107 mg for spironolactone and warfarin, respectively. For527
spironolactone, the drug amount was found significantly different (P<0.05) from the labelled amount.528
No statistical effects were found for warfarin (N.S.).529
